Trial Profile
A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Irbesartan in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2015
Price :
$35
*
At a glance
- Drugs Gemigliptin (Primary) ; Irbesartan (Primary)
- Indications Diabetic nephropathies; Hypertension; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors LG Life Sciences
- 29 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Oct 2013 Planned end date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 24 Jul 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.